REALBIL - Retrospective Analysis of Real-World Efficacy of Oncological Therapies in Patients with Biliary Tract Cancer

REALBIL - Retrospective Analysis of Real-World Efficacy of Oncological Therapies in Patients with Biliary Tract Cancer - REALBIL

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00037622

Enrollment

584

Registered

2025-10-17

Start date

2025-08-04

Completion date

Unknown

Last updated

2025-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with biliary tract cancers will be examined (ICD codes C22-C24)

Interventions

Group 1: Patients with confirmed biliary tract cancer will be examined.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Confirmed diagnosis of biliary tract carcinoma Diagnosis between January 1, 2012 and December 31, 2024 At least one line of systemic therapy OR a follow-up of at least 12 months after diagnosis

Exclusion criteria

Exclusion criteria: Failure to meet the inclusion criteria

Design outcomes

Primary

Measure	Time frame
Progression-free survival (Disease-free survival)	—

Secondary

Measure	Time frame
Overall survival, toxicity, dose modifications, dose density	—

Countries

Germany

Contacts

Public ContactCarlo Maurer

TUM Universitätsklinikum, Klinik und Poliklinik für Innere Medizin II

carlo.maurer@tum.de+498941409321

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026